What Todd Blanche’s Attorney General Nomination Could Mean for Psychedelics
A recent JD Supra analysis looks at what Todd Blanche’s nomination for attorney general could mean for marijuana and psychedelic policy. The central point is narrow but important. Blanche’s confirmation would not, by itself, reschedule psilocybin, MDMA, ibogaine, or any other psychedelic substance.
But it could shape how quickly federal agencies act, how strongly recent drug policy changes hold, and whether the same federal machinery used for marijuana ever turns toward psychedelics.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Point | Why It Matters |
|---|---|
| Blanche’s nomination does not change psychedelic law. | Psychedelics remain Schedule I unless federal agencies complete a separate legal process. |
| Marijuana rescheduling may become more durable. | Blanche signed the recent order as acting attorney general, which may make reversal less likely. |
| Psychedelic rescheduling remains possible, not guaranteed. | Marijuana reform creates a federal example, but psilocybin and other compounds require separate reviews. |
| The attorney general still matters. | DOJ and DEA priorities can affect timing, enforcement, litigation, and future rulemaking. |
Marijuana First, Psychedelics Later
The article begins with marijuana because it offers the clearest federal example. Earlier this year, the Department of Justice issued a final order moving certain medical marijuana products from Schedule I to Schedule III.
That move matters for cannabis operators, tax treatment, banking, intellectual property, and federal oversight. But the article argues that Blanche’s nomination is less about whether that shift happened. It already did.
Instead, the question is whether the change holds. Blanche signed the order while serving as acting attorney general. If confirmed, he would likely have less incentive to unwind a policy he already helped put in place.
Why Psychedelics Are Different
Psychedelics did not move with marijuana. Psilocybin, MDMA, ibogaine, and other substances remain under Schedule I federal control.
Still, the marijuana order may change the conversation. It shows that federal agencies can move a controlled substance when science, law, and politics align.
That does not mean psychedelic rescheduling comes next. The article stresses that marijuana and psychedelics follow separate legal tracks. A decision on one substance does not force action on another.
The Role of Federal Agencies
The attorney general sits near the center of this process. DEA reports through the Department of Justice. HHS provides scientific and medical evaluation in scheduling reviews. The FDA handles drug approval.
That structure gives each agency a different role. It also means timing can depend on priorities inside the administration.
The article points to several signs of federal momentum. These include recent psychedelic research efforts, priority review activity, and an executive order focused on reducing barriers to psychedelic drug development.
What This Means Now
The main takeaway is measured. Blanche’s confirmation would not legalize psychedelic therapy. It would not approve any drug. It would not automatically move psilocybin or any other compound out of Schedule I.
But personnel still matters in federal drug policy. The attorney general can influence enforcement, defend or revisit agency decisions, and affect whether pending rescheduling efforts move forward.
For psychedelic medicine, the article frames this moment as one of possibility, not certainty. The federal government has shown it can act. The next question is whether it will choose to act again.
